3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
2
Phase EARLY_PHASE1
1
Phase 3
1
Status
Completed
2
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Breast Neoplasms
23
Ovarian Neoplasms
18
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
9
Prostatic Neoplasms
9
Pancreatic Neoplasms
8
Neoplasms
8
Fallopian Tube Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
4
Advanced Solid Tumors
4
Small Cell Lung Carcinoma
3
Recurrence
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Squamous Cell
3
Solid Tumors
2
Sarcoma
2
Neuroendocrine Tumors
2
Lymphoma
2
Lung Neoplasms
2
Hodgkin Disease
2
Fanconi Anemia, Complementation Group D1
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumours
2
Advanced Solid Tumor
2
Advanced Cancer
2
Triple Negative Metastatic Breast Cancer
1
Thymoma
1
Thrombocytosis
1
Solid Tumor
1
Interventions
Doxorubicin
27
Cyclophosphamide
26
Radiotherapy
16
Gemcitabine
16
Filgrastim
11
pembrolizumab
10
pazopanib
10
Radiation
9
Docetaxel
9
Cisplatin
9
fludarabine
7
Trabectedin
7
Ipilimumab
7
Ifosfamide
7
Granulocyte Colony-Stimulating Factor
7
Etoposide
7
Carboplatin
7
Busulfan
7
Bevacizumab
7
olaratumab
6
Temozolomide
6
Peripheral Blood Stem Cell Transplantation
6
Nivolumab
6
Mesna
6
Melphalan
6
selinexor
5
Leucovorin
5
Irinotecan
5
Celecoxib
5
Bortezomib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Sarcoma
×
olaparib
×
Clear all
NCT02787642
2026-02-25
RADIOSARP
Institut Bergonié
Phase 1
Completed
41 enrolled
15 charts
NCT02398058
2021-04-14
TOMAS
Italian Sarcoma Group
Phase 1
Completed
50 enrolled